PMID- 15246539
OWN - NLM
STAT- MEDLINE
DCOM- 20040809
LR  - 20161124
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 365
IP  - 3
DP  - 2004 Jul 29
TI  - Opposite conditioned place preference responses to endomorphin-1 and 
      endomorphin-2 in the mouse.
PG  - 157-61
AB  - An unbiased conditioned place preference paradigm was used to evaluate the reward 
      effect of selective endogenous mu-opioid ligands, endomorphin-1 and 
      endomorphin-2, in male CD-1 mice. Pre- and post-conditioning free-movement were 
      measured on day 1 and day 5, respectively. Conditioning sessions were conducted 
      twice daily from day 2 through day 4 consisting of the alternate injection of 
      conditioning drug or vehicle. Intracerebroventricular (i.c.v.) injection of 
      endomorphin-1 (0.3-10 microg) induced place preference in a dose-dependent 
      manner; whereas, endomorphin-2 (1-10 microg) dose-dependently induced place 
      aversion. Both endomorphin-1-induced place preference and endomorphin-2-induced 
      place aversion were blocked by pretreatment i.c.v. with mu-opioid receptor 
      antagonist, beta-funaltrexamine. Selective delta-opioid receptor antagonist, 
      naltrindole, co-administered i.c.v. with endomorphin-1 or endomorphin-2 did not 
      affect reward effect. However, endomorphin-2-induced place aversion, but not 
      endomorphin-1-induced place preference, was blocked by the i.c.v.-administered 
      selective kappa-opioid receptor antagonist, WIN 44,441-3. It is concluded that 
      endomorphin-1 produces conditioned place preference, which is mediated by the 
      stimulation of mu-, but not delta- or kappa-opioid receptors, while endomorphin-2 
      produces conditioned place aversion, which is mediated by the stimulation of mu- 
      and kappa-, but not delta-opioid receptors.
FAU - Wu, Hsiang-en
AU  - Wu HE
AD  - Department of Anesthesiology, Medical College of Wisconsin, Medical Education 
      Building, M4308 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
FAU - MacDougall, Ryan S
AU  - MacDougall RS
FAU - Clithero, Andrew D
AU  - Clithero AD
FAU - Leitermann, Randy J
AU  - Leitermann RJ
FAU - Terashvili, Maia
AU  - Terashvili M
FAU - Tseng, Leon F
AU  - Tseng LF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Azocines)
RN  - 0 (Ligands)
RN  - 0 (Oligopeptides)
RN  - 0 (Receptors, Opioid, delta)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 0 (Receptors, Opioid, mu)
RN  - 0 (endomorphin 1)
RN  - 3PH5M0466G (endomorphin 2)
RN  - 5S6W795CQM (Naltrexone)
RN  - 72782-05-9 (beta-funaltrexamine)
RN  - X9BMD58553 (quadazocine)
SB  - IM
MH  - Animals
MH  - Azocines/pharmacology
MH  - Conditioning, Operant/*drug effects
MH  - Injections, Intraventricular
MH  - Ligands
MH  - Male
MH  - Mice
MH  - Naltrexone/*analogs & derivatives/pharmacology
MH  - Oligopeptides/administration & dosage/metabolism/*pharmacology
MH  - Receptors, Opioid, delta/antagonists & inhibitors
MH  - Receptors, Opioid, kappa/antagonists & inhibitors
MH  - Receptors, Opioid, mu/antagonists & inhibitors/metabolism
EDAT- 2004/07/13 05:00
MHDA- 2004/08/10 05:00
CRDT- 2004/07/13 05:00
PHST- 2003/09/05 00:00 [received]
PHST- 2004/03/28 00:00 [revised]
PHST- 2004/03/31 00:00 [accepted]
PHST- 2004/07/13 05:00 [pubmed]
PHST- 2004/08/10 05:00 [medline]
PHST- 2004/07/13 05:00 [entrez]
AID - S0304394004005397 [pii]
AID - 10.1016/j.neulet.2004.03.093 [doi]
PST - ppublish
SO  - Neurosci Lett. 2004 Jul 29;365(3):157-61. doi: 10.1016/j.neulet.2004.03.093.